study design - randomised, blinded, placebo controlled trial
7705 postmenopausal women with osteoporosis were included in the trial - exclusion criteria included history of breast or endometrial cancer or thromboembolic disorder, postemenopausal symptoms, other bone diseases and endocrine disorders (except hypothyroidism and type 2 diabetes)
patients received calcium and vitamin D (calcium 500mg/d and cholecalciferonl 400 to 600 IU/d). Patients were randomised also to receive placebo, or raloxifene 60mg/d or raloxifene 120mg/d
conclusion - this trial provides evidence that raloxifene prevented vertebral fractures in postmenopausal women with osteoporosis. The reduction in vertebral fracture risk was greater if a woman had had a previous vertebral fracture. Of note is the trial evidence that alendronate reduced fracture risk at the spine AND the hip in postmenopausal women with osteoporosis who had had previous vertebral fractures
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.